BioStock Studio: Scandion Oncology brings in New CEO

21 September 2020 - 09:56

Scandion Oncology’s top candidate, SCO-101, is currently in a phase II clinical trial with metastatic colorectal cancer patients. As the study progresses, the company is beginning a new phase in its development program. In light of this, the company has appointed Bo Rode Hansen as CEO, while former CEO Nils Brunner takes the role as CSO, to strengthen its executive leadership. Both Rode Hansen and Brunner came to the BioStock studio to discuss the change.

Watch the full interview with Scandion Oncology's CEO Bo Rode Hansen and CSO Nils Brünner at

This is a press release from BioStock - Connecting Innovation & Capital.

Provided by: Cision
Spotlight (Sweden)
Scandion Oncology A/S
Scandion is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has shown to improve the effect of certain standard cancer treatments during preclinical studies. The head office of the company is located in Copenhagen....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date